Allergy Therapeutics PLC Notice of Results (1190X)
August 08 2018 - 2:01AM
UK Regulatory
TIDMAGY
RNS Number : 1190X
Allergy Therapeutics PLC
08 August 2018
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Notice of Preliminary Results
8 August 2018 Allergy Therapeutics (AIM:AGY), the fully
integrated commercial biotechnology company specialising in allergy
vaccines, will issue its preliminary results for the year ended 30
June 2018 on Wednesday 26 September 2018.
Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Chief
Financial Officer, will hold a presentation and conference call for
analysts on the day of results at 10:30am BST at the offices of
Panmure Gordon & Co, One New Change, London, EC4M 9AF.
Please contact Consilium Strategic Communications for further
details.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Emma Earl, Corporate Finance
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia
Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial
biotechnology company focussed on the treatment and diagnosis of
allergic disorders, including immunotherapy vaccines that have the
potential to cure disease. The Group sells proprietary and third
party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional fourteen
countries. Its broad pipeline of products in clinical development
include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to
boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics
is headquartered in Worthing, UK with more than 11,000m2 of
state-of-the-art MHRA-approved manufacturing facilities and
laboratories. The Group, which has achieved double digit compound
annual growth since formation, employs c.500 employees and is
listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NORKMGGRVNKGRZM
(END) Dow Jones Newswires
August 08, 2018 02:01 ET (06:01 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024